Influence of personalized extended interval dosing on the natalizumab wearing-off effect - a sub-study of the NEXT-MS trial by Toorop, A.A., Wessels, M.H.J., Gelissen, L.M.Y., Hoitsma, E., Zeinstra, E.M.P.E., van Rooij, L.C., van Munster, C.E.P., Vennegoor, A., Mostert, J.P., Wokke, B.H.A., Kalkers, N.F., Hoogervorst, E.L.J., van Eijk, J.J.J., Roosendaal, C.M., Kragt, J.J., Eurelings, M., van Genugten, J., Nielsen, J., Sinnige, L.G.F., Kloosterziel, M.E., Arnoldus, E.P.J., van Dijk, G.W., Bouvy, W.H., Strijbis, E.M.M., van Oosten, B.W., de Jong, B.A., Lissenberg-Witte, B.I., Rispens, T., Uitdehaag, B.M.J., Killestein, J., van Kempen, Z.L.E.

Get full text

Cross-sectional and longitudinal correlations between the Arm Function in Multiple Sclerosis Questionnaire (AMSQ) and other outcome measures in multiple sclerosis by Molenaar, P.C.G., Strijbis, E.M.M., van Munster, C.E.P., Uitdehaag, B.M.J., Kalkers, N.F.

Get full text